Who would have thought that genes and cells can be manipulated in such a way to treat and cure compromising diseases? Cell gene therapies, also known as monoclonal treatment, have brought a new era in the biotech industry as a way of treatment for many compromising diseases like cancer, diabetes, genetic disorders, blindness, muscular dystrophy, and even Alzheimer’s. Now, these therapies are aiming to treat COVID-19.
This post is the second in my series covering the pressing concern of cross-contamination in the vaccine industry. For background on the subject, visit my original post, “Sources of Cross-Contamination in Vaccine Production.”
As more vaccines for COVID-19 emerge, safety in the vaccine production process is crucial. Any foreign matter entering the vaccine production process raises major safety concerns, and contamination is a common occurrence and a public health risk.
All of us who work in the Biotech industry, including those of us at EG Life Sciences, face daily challenges to maintain an aseptic environment. Rigorous safety standards are in place to avoid any cross-contamination and/or any foreign matter being introduced to the vaccine production process. However, there is still a chance that this could happen.